Filing Analysis
Anika Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release issued on July 29, 2026.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: July 29, 2026.
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Anika Therapeutics entered into a Fifth Amendment to its existing revolving credit agreement with Bank of America, N.A. on July 10, 2026. The amendment modifies the terms of an existing facility that provides up to $50 million in senior revolving credit, with provisions for potential additional commitments.
🚩 Red Flags
- The credit facility is secured by a first priority lien on substantially all of the company's assets.
📋 Key Facts
- Entered into Fifth Amendment to Credit Agreement on July 10, 2026.
- Existing revolving line of credit was originally dated October 24, 2017.
- Current senior revolving line of credit is $50.0 million with a maturity date of July 10, 2031.
- The agreement allows for an additional $50.0 million in commitments (up to $100.0 million aggregate) subject to lender approval.
- Interest rates are based on SOFR plus a margin ranging from 0.25% to 1.25%, depending on the consolidated leverage ratio.
- Lenders hold a first priority lien and security interest in substantially all company assets, excluding certain intangibles.
Anika Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. The meeting included the election of three directors and shareholder approval for amendments to the company's Omnibus Incentive Plan and Employee Stock Purchase Plan (ESPP).
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 18, 2026, with 84.14% of voting power represented.
- Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending Dec 31, 2026.
- Stockholders approved increasing shares reserved under the 2017 Omnibus Incentive Plan from 5,760,000 to 6,110,000.
- Stockholders approved increasing shares reserved under the 2021 ESPP from 200,000 to 400,000.
- Election of Gary P. Fischetti, John B. Henneman, III, and Stephen D. Griffin as Class III directors.
Anika Therapeutics announced its Q1 2026 financial results and the upcoming resignation of two directors, William R. Jellison and Dr. Glenn R. Larsen. Following their departures at the 2026 Annual Meeting, the company will reduce its board size from nine to seven members.
🚩 Red Flags
- Simultaneous resignation of two board members.
- Reduction in total board size from nine to seven members.
- Multiple 8-K items (2.02 and 5.02) reported in a single filing.
📋 Key Facts
- Q1 2026 financial results were announced via press release on April 29, 2026.
- Directors William R. Jellison (Class I) and Glenn R. Larsen (Class II) notified the board of their resignations on April 24, 2026.
- The resignations are effective as of the company's 2026 annual meeting of stockholders.
- The Board of Directors will decrease in size from nine to seven members following the resignations.
- The company reported that neither resignation involved a disagreement with management or the board.
Anika Therapeutics announced the departure of David Colleran, Executive Vice President, General Counsel, and Corporate Secretary, effective May 1, 2026. The company also reported its fourth quarter and full-year 2025 financial results in the same filing.
📋 Key Facts
- David Colleran will remain with the company through an anticipated separation date of May 1, 2026.
- Colleran entered into a Transitional Services and General Release of Claims Agreement on February 26, 2026.
- He will receive severance benefits as specified in his Executive Retention Agreement dated December 12, 2024.
- Equity awards will continue to vest during the transition period through May 1, 2026.
- The company concurrently released Q4 and FY 2025 financial results via Item 2.02.
Anika Therapeutics announced a leadership transition where CEO Cheryl R. Blanchard will step down to become Executive Chair on February 1, 2026, and be succeeded by current CFO/COO Steve Griffin. The filing also includes reaffirmed full-year 2025 guidance and the resignation of director Susan N. Vogt.
🚩 Red Flags
- CEO transition occurring alongside a significant decline in OEM Channel revenue (expected down 16-20% YoY).
- Potential cash outflow for CEO separation package (18 months of salary paid over 24 months).
- Board member resignation (Susan N. Vogt) coinciding with the leadership change.
📋 Key Facts
- Cheryl R. Blanchard to transition from CEO to Executive Chair on February 1, 2026, for a 12-month term.
- Steve Griffin (current EVP, CFO, and COO) appointed as new President and CEO effective February 1, 2026.
- Blanchard's separation includes 18 months of base salary paid over 24 months and continued equity vesting through January 31, 2028.
- Griffin to receive a target annual bonus of 75% of his $690,000 base salary and an equity award with a target value of $2.45 million.
- Director Susan N. Vogt resigned from the Board effective February 1, 2026.
- Reaffirmed 2025 Commercial Channel revenue guidance: $47M - $49.5M (up 12-18% YoY).
- Reaffirmed 2025 OEM Channel revenue guidance: $62M - $65M (down 16-20% YoY).
- Expected 2025 Adjusted EBITDA margin: +3% to -3% of revenue.
Anika Therapeutics announced its Q3 2025 financial results and a significant regulatory milestone regarding its Hyalofast product. The company has filed the final module of its Premarket Approval (PMA) application for Hyalofast following successful Phase III clinical trial results.
📋 Key Facts
- Released Q3 2025 financial results on November 5, 2025.
- Filed the third and final module of its Premarket Approval (PMA) application for Hyalofast.
- Reported positive results from U.S. pivotal Phase III FastTRACK clinical trial for Hyalofast.
- Hyalofast is a resorbable, hyaluronic acid-based scaffold used for treating articular cartilage defects in the knee.
Anika Therapeutics, Inc. filed an 8-K to furnish its second quarter 2025 financial results press release. This is a routine earnings announcement filing.
📋 Key Facts
- Report date: July 30, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Anika Therapeutics, Inc. issued a press release regarding topline results from its U.S. pivotal FastTRACK Phase III study for Hyalofast cartilage repair scaffold and provided a general program update.
📋 Key Facts
- Announcement of topline results from the U.S. pivotal FastTRACK Phase III study.
- The study focuses on the Hyalofast cartilage repair scaffold.
- Filing includes a program update alongside clinical trial data.
Anika Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 20, 2025. Key outcomes included the election of three directors and the ratification of Deloitte & Touche LLP as independent auditors.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 20, 2025, with 86.13% of voting power represented (12,351,806 shares).
- Stockholders approved an amendment to the 2017 Omnibus Incentive Plan, increasing reserved shares by 475,000 (from 5,285,000 to 5,760,000).
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Dr. Cheryl R. Blanchard, Joseph H. Capper, and Dr. Glenn R. Larsen were elected to the Board of Directors (Class II) through 2028.
- Shareholders approved executive compensation on a non-binding advisory basis.
Anika Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notice that a press release containing these results was issued on May 9, 2025.
📋 Key Facts
- Report date: May 9, 2025
- Reporting period: First quarter ended March 31, 2025
- The filing includes Exhibit 99.1 containing the full press release of financial results.
- Filed under Item 2.02 (Results of Operations and Financial Condition).
Anika Therapeutics announced the departure of its Chief Operations Officer, Anne Nunes, effective April 25, 2025. The company has decided to eliminate the COO position entirely rather than replacing her.
🚩 Red Flags
- Elimination of a C-suite position (COO) can sometimes indicate internal restructuring or cost-cutting measures.
- Increased workload for the CFO/COO, which may create operational bottlenecks if the transition is not seamless.
📋 Key Facts
- Anne Nunes (COO) is departing effective April 25, 2025.
- Ms. Nunes will receive severance benefits per her existing Executive Retention Agreement.
- The Chief Operations Officer position is being eliminated and will not be refilled.
- Stephen Griffin (EVP, CFO, and COO) will assume responsibility for manufacturing and operations functions.
- Mr. Griffin's annual compensation remains unchanged despite the increased scope of responsibilities.
Anika Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 12, 2025
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Anika Therapeutics, Inc. has completed the sale of its wholly-owned subsidiary, Parcus Medical, LLC, to Medacta Americas Manufacturing, Inc. The transaction was finalized on March 7, 2025.
🚩 Red Flags
- Divestiture of a wholly-owned subsidiary may indicate a strategic shift or a need for immediate liquidity in a micro-cap context.
📋 Key Facts
- Completed sale of all outstanding equity interests of Parcus Medical, LLC on March 7, 2025.
- The buyer is Medacta Americas Manufacturing, Inc.
- Immediate cash consideration received at closing was $4,500,000.
- Total aggregate consideration is subject to customary post-closing adjustments.
Anika Therapeutics, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024.
📋 Key Facts
- The filing was made on October 31, 2024.
- Covers the third quarter ended September 30, 2024.
- Financial results were released via press release (Exhibit 99.1).
Anika Therapeutics, Inc. completed the sale of its wholly-owned subsidiary, Arthrosurface Incorporated, to Phoenix Brio, Incorporated on October 31, 2024.
🚩 Red Flags
- The primary consideration is a $7M non-interest bearing promissory note, which may indicate liquidity constraints or less certainty than cash at closing.
- Sale of a wholly-owned subsidiary often signals a strategic pivot or a need to raise capital/deleveraging.
📋 Key Facts
- Transaction closed on October 31, 2024.
- Buyer (Phoenix Brio, Inc.) delivered a ten-year non-interest bearing promissory note for $7,000,000.
- Company is eligible for quarterly Revenue Payments based on net sales of certain products for up to 5 years.
- Potential 'Buy-Out Payment' option for Buyer: the greater of $14,000,000 or 10x the previous year's Revenue Payments.
- Company also retains a percentage of gross proceeds from third-party sales of certain products within 24 months.
Anika Therapeutics, Inc. filed an 8-K to furnish its second quarter 2024 financial results via a press release. The filing is a standard earnings announcement and does not contain material changes to corporate structure or unexpected news.
📋 Key Facts
- The company announced financial results for the second quarter ended June 30, 2024.
- Results were released on August 8, 2024.
- The filing includes Exhibit 99.1 containing the full press release.
Anika Therapeutics, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on July 9, 2024. The meeting included the election of three Class I directors and the ratification of Deloitte & Touche LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on July 9, 2024.
- Voting power represented: 83.37% (12,387,064 shares present out of 14,857,369 entitled to vote).
- Sheryl L. Conley, William R. Jellison, and Stephen O. Richard were elected as Class I directors.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
- Stockholders approved executive compensation on a non-binding advisory basis.
Anika Therapeutics entered into a Cooperation Agreement with the Investor Group (Caligan Partners LP, et al.), resulting in an expansion of the Board of Directors and the appointment of two new independent directors. The agreement includes significant standstill provisions for the investors and a $40 million share repurchase program authorized through June 2026.
🚩 Red Flags
- Board expansion often indicates pressure from activist investors or significant shareholder dissatisfaction.
- The agreement includes a 'Standstill Period' which is a common defensive measure used during investor conflicts.
- Large share repurchase program ($40M) in a micro-cap context can sometimes be used to defend against hostile takeovers rather than purely for capital efficiency.
📋 Key Facts
- Board size increased from eight to ten directors to accommodate William Jellison (Class I) and Joseph Capper (Class II).
- New directors will serve on the Capital Allocation Committee, which will expand to five members.
- The Company authorized a $40,000,000 share repurchase program to be completed by June 30, 2026.
- $15,000,000 of the buyback is to be executed via a Rule 10b5-1 plan initiated by May 31, 2024.
- Investor Group agreed to vote in accordance with Board recommendations during a 'Standstill Period'.
- Investor Group is subject to ownership limits (max 9.7%) and non-solicitation/non-disparagement clauses.
Anika Therapeutics announced a leadership transition in its finance department, with CFO Michael Levitz resigning to serve as an advisor through year-end 2024. He will be replaced by Stephen Griffin, who joins as EVP and CFO effective June 3, 2024.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (though mitigated by a transitional advisory period).
- Cash outflow for CFO separation ($100,000 one-time payment).
📋 Key Facts
- Michael Levitz resigned as EVP, CFO and Treasurer on May 2, 2024.
- Levitz will remain in an advisory role with an anticipated end date of December 31, 2024.
- Stephen Griffin appointed as new EVP, CFO and Treasurer effective June 3, 2024.
- Griffin's compensation includes a $500,000 base salary and up to 60% target annual bonus.
- Griffin will receive $2,000,000 in equity awards (RSUs and stock options) vesting over three years.
- Levitz will receive a one-time payment of $100,000 as part of his separation agreement.
Anika Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notification of the release of quarterly earnings data.
📋 Key Facts
- Report date: May 8, 2024
- Reporting period: First quarter ended March 31, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Anika Therapeutics, Inc. filed an 8-K to announce its financial results for the fourth quarter and full fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 13, 2024
- Reporting period: Q4 and Full Year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) detailing financial results.
Anika Therapeutics announced the planned retirement of Board Director Jeffery S. Thompson, effective at the 2024 Annual Meeting. Concurrently, independent director John B. Henneman, III has been appointed as Chair of the Board.
🚩 Red Flags
- None identified; director stated departure is not due to any disagreement with Company operations, policies, or practices.
📋 Key Facts
- Jeffery S. Thompson to retire from the Board after 13 years of service.
- Retirement effective date: End of current term (at the 2024 Annual Meeting of Stockholders).
- John B. Henneman, III appointed Chair of the Board, effective immediately.
- The Board will consist of seven directors following the retirement and upcoming elections.